Antibiotics Sciences SA (Gnubiotics), announced today a strategic partnership agreement with ADM, a global leader in human and animal nutrition. The strategic partnership is centered on the commercialization of innovative microbiome solutions for companion animal health and wellbeing.
This strategic partnership provides ADM with unique access to cutting-edge technologies and a pipeline of microbiome-focused innovation from Gnubiotics.
We´re excited about this partnership with Gnubiotics, and the capabilities they bring, enabling pet parents to better understand their pets’ microbiome. With this knowledge, ADM can leverage its comprehensive pantry of pet and animal well-being solutions to improve individual pet health through precise nutrition and supplementation, said Gustavo Zenaide, Vice President of ADM Pet & Animal Well-being.
The gut microbiome is essential to the health and well-being of companion animals. Study data from Gnubiotics show Animal Milk Oligosaccharides(A.M.O.s) manufactured by Gnubiotics helped protect the microbiome of dogs from the negative effects of antibiotics.In 2021, Gnubiotics also announced patents covering microbiome-based markers to predict, diagnose and treat feline obesity, a major cause of diabetes and chronic kidney disease (CKD) in felines.
We are pleased to work with ADM, a global leader in human and animal health and nutrition, said Yemi Adesokan, CEO and Co-Founder, of Antibiotics. We have developed products that have functional and clinically demonstrated applications for animal health and well-being. This strategic partnership with ADM is a major accomplishment for Gnubiotics as it represents a validation of our science and technology. We are excited to collaborate with ADM to continue to develop and bring to market, data-driven microbiome-targeted solutions.